The RIGHT Institute, a branch of the National Institute of Health and Medical Research based at the French Blood Bank in Besançon, developed in 1998 one of the first gene-modified cell therapy in the context of bone marrow transplantation to tackle leukemia while preventing host rejection. From that time, the RIGHT institute continuously developed innovative therapies from gene-modified cells to biological drugs, including other cell therapies and RNA-based anti-tumor vaccines.
More recently, two CAR-T cell-based approaches emerged from the RIGHT institute, boosted by the scientific background of the local researchers, the economic local tissues, and the expertise of the local CRO, CDMO, and the ATMP pharmaceutical suites from the French Blood Bank. Based on these successes and also on the hurdles faced during the translational development phase to bring these innovations to the patient bedside, we decided Dr. Sylvain Perruche and Dr. Christophe Ferrand, to organize a congress dedicated to sharing translational experiences to develop an innovative drug for the market.
The first edition in 2021 in Besançon welcomed the world’s leading players specialized in the development of innovative therapies, from their production to their regulatory framework. Clinicians and scientists from the private and academic spheres presented their latest scientific advances on the development of CAR-T cells, stem cells, or pluripotent cells, focusing on their transfer to clinical trials and the challenges of their industrial production.
The success of this first edition of the « Innovative Therapies Days » based on the quality of the invited speakers, and exchanges between partners at the Exhibitors’ Village and during B2B sessions, pushed us to transform those days into a series of annual international meetings.
Now,a solid scientific board composed of Dr. Sylvain Perruche (RIGHT Institute), Dr. Christophe Ferrand (RIGHT Institute), Dr. Sylvie Mercier (RD-biotech), Dr. Agnès Fourcot (PMT), and organizers (Marie-Elisabeth Benoit & Anthony Nolot, PMT) board select the coming innovative therapies to propose a high-level program every year.
The Innovative Therapies Days will make the connection between the academic and the industrial worlds: from research, to clinical trials, to industrialisation.
17:00-21:00 : WELCOME EVENING & POSTER SESSION (BIO INNOVATION)
Poster session, visit Bio Innovation, discover the regional biocluster & foodtruck
8:30 : REGISTRATION AND WELCOME COFFEE (KURSAAL BALLROOM)
9:00 : WELCOME ADRESS AND INTRODUCTION (KURSAAL)
Dr. Sylvain Perruche, Med Inn Pharma, Besançon, FR
Laurent Deschamps, PMT President, Besançon, FR
Representative of the President of Grand Besançon Métropole
Representative of the President of the Bourgogne Franche Comté Region
09:20-12:30 : SESSION #1 « UPCOMING INNOVATIVE THERAPIES »
Chairpersons : Dr Sylvain Perruche and Dr Susanne Behlke, Med’Inn’Pharma, Besançon, FR
09:20 : Translational potential of human platelet secretome and EVs
Pr Thierry Burnouf, Taipei Medical University’s College, Taiwan
09:50 : Evergel, an innovative extracellular vesicle-based therapy
Dr Julien Branchu, Everzom, Paris, FR
(10:20 : GOLD SPONSOR SMALL TALK)
10:25 : BREAK – EXHIBITION HALL
11:15 : Reprogramming innate immunity by early apoptotic cells (Allocetra-OTS)
Pr Dror Mevorach, Hadassah Medical Center, Jerusalem, ISR
11:45 : ASCALLO, a new alternative to treat refractory GVHD ?
Dr Anaick Moisan, Etablissement Français du Sang, Saint Ismier, FRA
12:20-14:00 : LUNCH
13:00-14:30 : Exhibition Hall – B2B MEETINGS
14:15-14:45 : SYMPOSIUM – CELL AND GENE THERAPIES: THE PATH AHEAD
Emmanuelle Cameau, Cytiva
14:45-17:30 : SESSION #2 “ CAR-T CELLS AND BEYOND ”
Chairpersons : Dr Marina Deschamps and Dr Christophe Ferrand, RIGHT Institute, Besançon, FR
14:45 : How can you register your academic CAR-T cell product in the EU
Dr Julio Delgado, Clinic Barcelona, Barcelona, SP
15:15 : From bench to bedside: Successfully translating science to therapy
MD Jens Hasskarl, Advesya, Paris, FR
(15:45 : GOLD SPONSOR SMALL TALK)
15:50 : BREAK – EXHIBITION HALL
16:30 Antigen Presenting Cell Mimetic Lipid Nanoparticles for Rapid mRNA CAR-T Cell Cancer Immunotherapy
Dr Christian Figueroa-Espada, University of Pennsylvania, Philadelphia, USA
17:00 : Epigenetic reprogramming via SUV39H1 inactivation for improved CAR T cell persistence and efficacy in primary central nervous system lymphoma
Dr Jaime Fuentealba, CellAction, Paris, FR
17:40-19:30 : B2B MEETINGS OR VISIT OF BESANÇON (on registration only)
19:30 : COCKTAIL (KURSAAL)
(on registration only)
20:00 : EVENING RECEPTION (KURSAAL)
(on registration only)
8:30 : WELCOME COFFEE (KURSAAL)
9:00-12:00 : SESSION #3 “PATHWAYS FOR INNOVATIVE THERAPIES”
Chairpersons : Dr Jérémy Magalon, AP-HM, Marseille and Dr Olivier Humbey, IQVIA, FR
09:15 : Upcoming title
Dr Geoffrey Richard, Mabdesign, Lyon, FRA
09:45 : CAR-T: pricing, efficiency and sustainability in France
Pr Gérard de Pouvourville, ESSEC Business School, Cergy-Pontoise, FRA
10:15 : BREAK- EXHIBITION HALL
11:00 : The challenges of translating Pluripotent Stem Cell-derived therapies compared to somatic cell therapies: from starting material to product purity
Dr Jo Mountford , Scottish National Blood transfusion service , Edinburgh, Scotland
11:30 : Use of External Comparator to engage & meet market stakeholders requirements
Nora Kleinman, IQVIA, Paris, FR
12:00-14:00 : LUNCH
12:40-14:00 : Exhibition Hall – B2B MEETINGS
14:00-16:30 : SESSION #4 “CELL AND GENE THERAPIES”
Chairpersons : Pr John De Vos, INSERM U1183, CHU Montpellier and Dr Mathilde Girard, Urgo, Chenôve, FR
14:00 : Successful clinical development of a cell-based drug in canine osteoarthritis
Dr Stephane Maddens, Vetbiobank, Marcy-L’Etoile, FR
14:30 : Optimizing tumor reactivity and functions of therapeutic T cells
Dr Nathalie Labarriere, INCIT, UMR1302, Nantes, FR
15:00 -15h30 : BREAK- EXHIBITION HALL
15:30 : Alloevasion approaches to IPSC-derived cell therapies
Dr Nikolaus Trede, Century Therapeutics, Philadelphia, USA
16:00 : Advancing CD8+ Treg cell therapy to the clinic
Dr Carole Guillonneau, Center for Research in Transplantation and Translational Immunology, Nantes, FRA
16 :45-16h50 : CONCLUSION & END OF CONGRESS
Dr Christophe Ferrand, RIGHT Institute, Besançon, FR
17:00-17:45 : B2B MEETINGS
16h50 – 18:00 BEER PARTY ( on registration only)
Dr Marina DESCHAMPS – Right Institute (Besançon, FR), Dr Christophe FERRAND – Right Institute (Besançon, FR), Sylvain PERRUCHE – MedInn Pharma (Besançon, FR),
Mathilde Girard is a stem cell specialist, specialized in bioproduction and automation for cell therapy applications. After a PhD in Human Genetics she specialized in pluripotent stem cells applications at the I-Stem institute in Evry. She notably led a research...
En savoir +Julien Branchu focused his scientific career on the discovery of innovative therapeutic targets that could improve the daily lives of patients. After several internships in neuroscience field, he joined Pr. F. Charbonnier's group for his PhD. Using in vitro and...
En savoir +Thierry Burnouf, PhD, is a Distinguished Professor and Vice-Dean at the College of Biomedical Engineering, Taipei Medical University, Taiwan. He established and leads a research lab focusing on platelets and extracellular vesicles for regenerative medicine, cell therapy, and drug delivery....
En savoir +Dr. Christian G. Figueroa-Espada is a distinguished biomedical engineer and cancer researcher dedicated to advancing therapeutic strategies through innovative nanotechnology and interdisciplinary approaches. He completed his Ph.D. in Bioengineering at the University of Pennsylvania, where his research focused on developing...
En savoir +Dr. Julio Delgado is the Head of the Oncoimmunotherapy Unit and consultant haematologist at Hospital Clínic, Barcelona (HCB), researcher at IDIBAPS Biomedical Research Institute, and associate professor at the University of Barcelona. He has been involved in the clinical development...
En savoir +Geoffrey joined MabDesign in 2017 and holds the position of Corporate Development Manager. His role involves developing strategic partnerships for the organisation and coordinating MabDesign's offerings, both internally and externally. In the field of research, he supports industry players by...
En savoir +Dr. Jaime Fuentealba obtained his PhD in Neuroscience in 2017 from Sorbonne Université, working at the Brain and Spine Institute in Paris. He then joined the team of Dr. Sebastian Amigorena at Institut Curie as a post-doctoral fellow and contributed...
En savoir +Nora is a Principal in the EMEA Medical Evidence Practice at IQVIA where she leads RWE consulting and evidence generation studies to improve healthcare through innovate real-world insights. Trained as an epidemiologist, she started her career in public health at...
En savoir +Prof de Pouvourville has graduated from Ecole Polytechnique in 1973 Formerly, he has led a career as a researcher in the field of health care economics and management, at Ecole polytechnique, at the French National School of Public Health and...
En savoir +Dr. Dror Mevorach is a Full Professor and Director of the Rheumatology-Immunology-Allergology Institute at Hadassah Medical Center, affiliated with the Hebrew University in Jerusalem, Israel. He obtained his medical degree cum laude from the Technion Institute, Haifa, Israel, in 1988....
En savoir +Stéphane Maddens is the founder and CEO of Vetbiobank, a clinical-stage biotech based in Lyon (France) and specialised in developing and manufacturing cell-based drugs for animal health. He holds a pharmacy degree specialised in cell therapy applied to hemato-oncology diseases...
En savoir +Jens Hasskarl is the chief medical officer of advesya, a French startup focused on developing lifesaving therapies. Prior to joining advesya, he was the chief medical officer of Tigen Pharma SA, a Swiss startup developing cellular therapies to fight solid...
En savoir +MD degree, Freiburg University Supervisor of MD thesis: Radvan Urbanek, magna cum laude DEA immunology, Institut Pasteur, Paris Supervisor: Pierre Andre Cazenave PhD Immunology, Universite Paris VII Supervisor: Raif Geha, summa cum laude Residency in Pediatrics, Children’s Hospital Boston Fellowship...
En savoir +Dr Anaïck Moisan, PharmD and PhD, is the pharmacist responsible for the production and the release of ATMP used in regenerative medicine and clinical trials, in the Cell Therapy and Engineering Unit of EFS Rhône Alpes, based in St Ismier,...
En savoir +Sebastian Amigorena is “Directeur de Recherche Classe Exceptionnelle” at CNRS, Director of the “Center of Immunotherapy for cancers” and the “Immune responses and cancer” Team at Institut Curie (Paris, France), in the Immunology Department "Immunity and Cancer" that he created...
En savoir +Nathalie Labarriere is Inserm Research Director, in charge of the team 3 « Anti-tumor immunosurveillance and immunotherapy» and deputy director of the INCIT Unit (Immunology and new concepts in Immunotherapy). She started working in 1990 on tumor immunology in Nantes...
En savoir +JCM is the Associate Director for Tissues, Cells and Advanced Therapies (TCAT) at the SNBTS and an Honorary Reader at University of Edinburgh. As an experienced experimental haematologist and stem cell biologist Jo’s focus is the assessment, development and translation...
En savoir +Susanne Behlke, PhD serves currently as Chief Scientific Officer at Med’Inn’Pharma applying more than 15 years of clinical research, early and late stage drug development experiences, which she gained in positions within the pharmaceutical industry working at companies like EUROFINS...
En savoir +Dr GUILLONNEAU is Director of Research CNRS, head of team 2 at the Center of Research in Transplantation and Translational Immunology (CR2TI) in Nantes, France and director of the FOCIS Center of Excellence Nantes University. After a Postdoc in the...
En savoir +The Innovative Therapies Days will make the connection between the academic and the industrial worlds: from research, to clinical trials, to industrialisation. CAR-T CELLS, CELL THERAPIES, CELL-DERIVED INNOVATIVE THERAPIES This session will cover a wide range of topics from cell...
Learn moreThe Innovative Therapies Days will make the connection between the academic and the industrial worlds: from research, to clinical trials, to industrialization. CAR-T CELLS Chimeric antigen receptor T cell (CAR-T) therapy has revolutionized the revolutionized the disease course of...
Learn moreThe Innovative Therapies Days will make the connection between the academic and the industrial worlds: from research, to clinical trials, to industrialisation. CAR-T CELLS (I) – (II) Chimeric Antigen Receptor T cells therapy (CAR-T) has revolutionized the course of disease...
Learn more